A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
Immuneering Corporation
Immuneering Corporation
Pfizer
AO GENERIUM
Adaptimmune
Karyopharm Therapeutics Inc
KitovPharma
Santa Maria Biotherapeutics
Novartis
Celldex Therapeutics
University of Pittsburgh
Merck Sharp & Dohme LLC
Bristol-Myers Squibb